/

CLYM

Climb Bio, Inc.Open

10.25−0.06 −0.58%USD

NasdaqGM · as of Oct 14, 12:01 ET · 15m delay

Open

10.19

Prev close

10.31

Day range

10.0910.64

52-week range

1.6418.33

Volume

236.71K0.17×

Mkt cap

588.72M

P/E ttm

—

Fwd P/E

-10.22

EPS ttm

-0.8200

Div yield

0.00%

Earnings

—

From 52w high

−44.08%

Price Chart

Yahoo Finance · delayed

CLYMOct 14, 2026O 10.19H 10.64L 10.09C 10.25−0.06 (−0.58%)Vol 236.71K

SMA 5013.81
SMA 20010.02

1Y change +412.50% since Oct 13, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

CLYM Climb Bio, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −4.30%
1 month: −29.60%
3 months: −26.10%
6 months: +18.50%
Year to date: +156.25%
1 year: +445.21%

Valuation & ownership

Market cap: 588.72M
Enterprise value: 410.36M
P/E (ttm): —
Forward P/E: -10.22
PEG ratio: —
Price / book: 2.46
Price / sales (ttm): —
EV / EBITDA: -6.35
EPS (ttm): -0.8200
EPS (forward): -1.00
Beta (5y monthly): -0.03
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 57.44M
Float: 38.74M
Short % of float: 23.86%
Short ratio (days): 5.36
Held by insiders: 0.18%
Held by institutions: 105.63%
Avg volume (3m): 1.36M
50-day average: 13.86
200-day average: 9.99
52-week change: +445.21%
S&P 500 52-week: +17.00%

Technicals (daily)

RSI (14): oversold 28.9
vs 50-day SMA: −25.79%
vs 200-day SMA: +2.28%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 7.52%
Realised vol (20d, ann.): 54.9%
From 52-week high: −44.08%
From 52-week low: +526.91%

ANR

Analyst Consensus

14 analysts

Consensus

Strong buy

1.13 on a 1 (strong buy) – 5 (sell) scale

Mean target

27.57

+168.99% implied

Low 18.00Median 26.50High 40.00

Recommendation trend

Now15 / 0 / 0
1m ago15 / 0 / 0

DES

About Climb Bio, Inc.

Yahoo Finance profile

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 28
Headquarters: Wellesley Hills, MA, United States
Website: climbbio.com
Officers: Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc CEO, President & Director
Dr. Susan Altschuller M.B.A., Ph.D. CFO & Principal Accounting Officer
Dr. Perrin Wilson B.S., Ph.D. Chief Business Officer

SEAS

Seasonality · CLYM

2021–2026 · monthly returns

Strongest month Apr +28.63%Weakest month Nov −13.03%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	11.7	60.0	-4.2	29.6	23.4	19.0	-8.7	15.4	-16.5	-10.6			+156.2%
2025	5.6	-23.7	-15.9	9.8	-11.9	5.1	12.9	59.3	-9.9	2.0	-7.8	111.6	+122.2%
2024	-5.2	6.6	0.4	158.8	8.7	-7.8	16.6	-15.7	-27.2	-24.9	-15.6	-44.3	−33.3%
2023	-4.6	1.7	-18.5	8.3	-7.0	-4.1	-4.3	-1.1	-0.8	0.0	-2.7	5.5	−26.4%
2022	-13.6	-0.3	-6.9	-62.3	21.2	-21.1	5.3	-3.8	5.6	1.2	-21.7	43.4	−64.9%
2021									-30.0	-3.1	-17.4	-27.3	−59.3%

INSD

Insider Activity · CLYM

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

138.8K shares

Sells, 6 months

130.9K shares

Net shares

+7.8K

Net change in insider shares

+8.30%

Date	Insider	Transaction	Shares	Value
Sep 27, 2026	Ra Capital Management, L.P.Beneficial Owner of more than 10% of a Class of Security	Conversion of Exercise of derivative security at price 1.29 - 7.89 per share.	70K	$195.10K
Sep 14, 2026	Thomas Stephen BasilDirector	Sale at price 13.67 per share.	100K	$1.37M
Jun 28, 2026	Brennan Aoife MChief Executive Officer	Sale at price 13.17 per share.	30.9K	$406.98K
Jun 25, 2026	Brennan Aoife MChief Executive Officer	—	68.8K	—
Feb 25, 2026	Thomas Stephen BasilDirector	Sale at price 7.00 - 7.01 per share.	50K	$350.25K
Feb 12, 2026	Thomas Stephen BasilDirector	Sale at price 5.23 - 5.81 per share.	100K	$529.13K
Jan 4, 2026	Ra Capital Management, L.P.Beneficial Owner of more than 10% of a Class of Security	Purchase at price 3.50 per share.	7.1K	$24.89K
Dec 11, 2025	Ra Capital Management, L.P.Beneficial Owner of more than 10% of a Class of Security	Purchase at price 2.18 - 2.86 per share.	314.6K	$754.74K
Aug 6, 2025	Thomas Stephen BasilDirector	Stock Award(Grant) at price 0.00 per share.	100.4K	—
Jun 29, 2025	Brennan Aoife MChief Executive Officer	Sale at price 1.22 per share.	20.6K	$25.15K
Jun 26, 2025	Brennan Aoife MChief Executive Officer	—	68.8K	—
Jun 26, 2025	Thomas Stephen BasilDirector	—	25.1K	—
Jun 19, 2025	Pimblett EmilyOfficer	Sale at price 1.24 per share.	1.2K	$1.54K
Jun 17, 2025	Pimblett EmilyOfficer	—	5K	—
Mar 26, 2025	Thomas Stephen BasilDirector	—	25.1K	—
Mar 19, 2025	Pimblett EmilyOfficer	Sale at price 1.31 per share.	1.2K	$1.57K
Mar 17, 2025	Pimblett EmilyOfficer	—	5K	—
Dec 30, 2024	Thomas Stephen BasilDirector	—	50.2K	—
Dec 18, 2024	Pimblett EmilyOfficer	Sale at price 2.02 per share.	1.2K	$2.50K
Dec 17, 2024	Pimblett EmilyOfficer	—	5K	—

13F

Investors Holding CLYM

latest 13F filings of 29 followed managers

Investors holding CLYM
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$2.5M	0.00%	192.70K	−11%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

CLYM

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

CLYM

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Climb Bio, Inc.

Seasonality · CLYM

Insider Activity · CLYM

Congress Trades · CLYM

Investors Holding CLYM

Investors Holding CLYM

Congress Trades · CLYM

Seasonality · CLYM

Insider Activity · CLYM

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Climb Bio, Inc.

Financial Snapshot

Earnings & Dividends

News